Array, Loxo to develop cancer drugs in potential $434M deal

Loxo Oncology and Array BioPharma agreed to co-develop the latter's preclinical drug candidate that targets an oncogenic activating mutation. The partners also agreed to collaborate in the discovery and development of small-molecule compounds against oncology targets chosen by Loxo. The deal entitles Array to as much $434 million in milestone fees plus sales royalties.

View Full Article in:

Daily Camera (Boulder, Colo.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN